Botulinum toxin in the treatment of orofacial tardive dyskinesia: A single blind study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 2, 2008, Pages 507-509

  Slotema, Christina W ^a   van Harten, Peter N ^b,c   Bruggeman, Richard ^c   Hoek, Hans W ^a,c,d  

^a PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^b Symfora Groep   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Antipsychotic agents; Botulinum toxin; Orofacial tardive dyskinesia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPHENAZINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MENTAL DEFICIENCY; ORGANIC PSYCHOSYNDROME; RECURRENT DISEASE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SINGLE BLIND PROCEDURE; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BOTULINUM TOXIN TYPE A; FACIAL MUSCLES; FEMALE; FUNCTIONAL LATERALITY; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MENTAL DISORDERS; MIDDLE AGED; MOVEMENT DISORDERS; PHYSICAL EXAMINATION; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 38749145225     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.10.004     Document Type: Article

References (12)

1. Baca-Garcia E., Stanilla J.K., Büchel C., Gattaz W.F., and de Leon J. Diurnal variability of orofacial dyskinetic movements. Pharmacopsychiatry 32 (1999) 73-75
2. Costa J., Espirito-Santo C., Borges A., Ferreira J.J., Coelho M., Moore P., et al. Botulinum toxin type A therapy for hemicial spasm. Cochrane Database Syst Rev 1 (2005)
3. Costa J., Espirito-Santo C., Borges A., Ferreira J.J., Coelho M., Moore P., et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev 1 (2005)
4. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 18 (1995) 197-214
5. Rapaport A., Sadeh M., Stein D., Levine J., Sirota P., Mosheva T., et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord 15 (2000) 352-355
6. Soares K.V., and McGrath J.J. The treatment of tardive dyskinesia: a systematic review and meta-analysis. Schizophr Res 39 (1999) 1-16
7. Truong D.D., Hermanowicz N., and Rontal M. Botulinum toxin in the treatment of tardive dyskinetic syndrome. J Clin Psychopharmacol 10 (1990) 438-439
8. Van Harten P.N., and Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord 21 (2006) 1276-1277
9. Van Harten P.N., Matroos G.E., Hoek H.W., and Kahn R.S. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curaçao Extrapyramidal Syndromes Study: I. Schizophr Res 19 (1996) 195-203
10. Van Harten P.N., Hoek H.W., Matroos G.E., and van Os J. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V. J Clin Psychiatry 67 (2006) 1920-1927
11. Wyatt R.J. Practical Psychiatric Practice: Forms and Protocols for Clinical Use. 2nd ed. (1998), American Psychiatric Press, Inc, Washington DC
12. Yasufuku-Takano J., Sakurai M., Kanazawa I., and Nagaoka M. Successful treatment of intractable tardive dyskinesia with botulinum toxin. J Neurol Neurosurg Psychiatry 58 (1995) 511-512